Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus | 65 | 2024 | 5702 | 5.970 |
Why?
|
Endocrinology | 25 | 2023 | 440 | 4.780 |
Why?
|
Patient-Centered Care | 23 | 2020 | 1435 | 3.610 |
Why?
|
Diabetes Mellitus, Type 2 | 43 | 2023 | 11699 | 2.190 |
Why?
|
Diabetes Mellitus, Type 1 | 19 | 2023 | 3323 | 2.180 |
Why?
|
Blood Glucose | 24 | 2022 | 6237 | 1.840 |
Why?
|
Primary Health Care | 18 | 2023 | 4537 | 1.780 |
Why?
|
Hypoglycemia | 7 | 2022 | 855 | 1.530 |
Why?
|
Diabetes Complications | 8 | 2018 | 1356 | 1.390 |
Why?
|
Hypoglycemic Agents | 19 | 2023 | 2861 | 1.320 |
Why?
|
Self Care | 10 | 2018 | 787 | 1.280 |
Why?
|
Family Practice | 3 | 2016 | 516 | 1.250 |
Why?
|
Hyperglycemia | 10 | 2022 | 1357 | 1.240 |
Why?
|
Pennsylvania | 13 | 2016 | 615 | 1.170 |
Why?
|
Case Management | 4 | 2013 | 287 | 1.150 |
Why?
|
Insulin | 18 | 2021 | 6569 | 1.120 |
Why?
|
Blood Glucose Self-Monitoring | 10 | 2022 | 430 | 1.030 |
Why?
|
Standard of Care | 23 | 2023 | 563 | 1.020 |
Why?
|
Podiatry | 2 | 2014 | 21 | 0.890 |
Why?
|
Education, Continuing | 1 | 2023 | 112 | 0.850 |
Why?
|
Glucagon | 3 | 2021 | 532 | 0.840 |
Why?
|
Fellowships and Scholarships | 2 | 2020 | 1058 | 0.820 |
Why?
|
Reference Standards | 19 | 2023 | 1018 | 0.800 |
Why?
|
Professional Role | 2 | 2014 | 305 | 0.760 |
Why?
|
Biomedical Technology | 2 | 2018 | 221 | 0.710 |
Why?
|
Competitive Bidding | 1 | 2019 | 17 | 0.690 |
Why?
|
Practice Management, Medical | 2 | 2018 | 197 | 0.690 |
Why?
|
Attitude of Health Personnel | 6 | 2016 | 3844 | 0.690 |
Why?
|
Reagent Strips | 1 | 2019 | 39 | 0.680 |
Why?
|
Health Educators | 1 | 2018 | 20 | 0.660 |
Why?
|
Disease Management | 6 | 2019 | 2448 | 0.650 |
Why?
|
Health Care Costs | 7 | 2024 | 3226 | 0.640 |
Why?
|
Organizational Innovation | 7 | 2018 | 559 | 0.640 |
Why?
|
Quality Improvement | 6 | 2023 | 3730 | 0.590 |
Why?
|
Blood Chemical Analysis | 1 | 2019 | 441 | 0.590 |
Why?
|
Patient Care Team | 7 | 2021 | 2527 | 0.580 |
Why?
|
Cooperative Behavior | 3 | 2016 | 1503 | 0.580 |
Why?
|
Motivation | 7 | 2017 | 1965 | 0.570 |
Why?
|
Emergency Medical Services | 2 | 2018 | 1904 | 0.560 |
Why?
|
Internet | 4 | 2015 | 3048 | 0.560 |
Why?
|
Humans | 145 | 2024 | 739398 | 0.560 |
Why?
|
Patient Education as Topic | 7 | 2017 | 2275 | 0.540 |
Why?
|
Models, Organizational | 7 | 2018 | 573 | 0.540 |
Why?
|
Models, Economic | 2 | 2016 | 723 | 0.520 |
Why?
|
Islets of Langerhans Transplantation | 2 | 2019 | 742 | 0.520 |
Why?
|
Health Care Reform | 4 | 2013 | 1258 | 0.500 |
Why?
|
Practice Guidelines as Topic | 7 | 2020 | 7274 | 0.480 |
Why?
|
Telemedicine | 6 | 2021 | 2844 | 0.470 |
Why?
|
Comprehensive Health Care | 1 | 2015 | 128 | 0.470 |
Why?
|
Career Choice | 1 | 2020 | 742 | 0.470 |
Why?
|
Nurses | 3 | 2014 | 2455 | 0.460 |
Why?
|
Quality Assurance, Health Care | 4 | 2014 | 2213 | 0.450 |
Why?
|
Societies, Medical | 19 | 2023 | 3739 | 0.450 |
Why?
|
Insulin Infusion Systems | 2 | 2005 | 212 | 0.440 |
Why?
|
Health Plan Implementation | 2 | 2016 | 351 | 0.430 |
Why?
|
United States | 29 | 2024 | 69573 | 0.420 |
Why?
|
Self-Help Groups | 1 | 2013 | 188 | 0.410 |
Why?
|
Insulin-Secreting Cells | 1 | 2019 | 889 | 0.410 |
Why?
|
Drug Costs | 1 | 2019 | 1115 | 0.400 |
Why?
|
Burnout, Professional | 1 | 2020 | 685 | 0.400 |
Why?
|
Health Priorities | 1 | 2014 | 380 | 0.400 |
Why?
|
Physicians | 3 | 2020 | 4539 | 0.400 |
Why?
|
Patient Protection and Affordable Care Act | 3 | 2016 | 1206 | 0.380 |
Why?
|
Health Services | 2 | 2024 | 757 | 0.370 |
Why?
|
Physician Assistants | 1 | 2013 | 194 | 0.370 |
Why?
|
Health Care Surveys | 2 | 2015 | 2448 | 0.370 |
Why?
|
Quality of Health Care | 8 | 2018 | 4365 | 0.350 |
Why?
|
Monitoring, Ambulatory | 3 | 2019 | 354 | 0.340 |
Why?
|
Organizational Culture | 1 | 2013 | 510 | 0.340 |
Why?
|
Academic Medical Centers | 2 | 2018 | 2749 | 0.340 |
Why?
|
Models, Psychological | 1 | 2013 | 809 | 0.330 |
Why?
|
Directive Counseling | 1 | 2010 | 166 | 0.330 |
Why?
|
Chronic Disease | 7 | 2016 | 9133 | 0.330 |
Why?
|
Interviews as Topic | 3 | 2016 | 2533 | 0.310 |
Why?
|
Clinical Trials as Topic | 3 | 2022 | 7897 | 0.310 |
Why?
|
Perioperative Care | 2 | 2012 | 995 | 0.290 |
Why?
|
Cholesterol, LDL | 3 | 2012 | 2334 | 0.290 |
Why?
|
Registries | 3 | 2009 | 8039 | 0.290 |
Why?
|
Diabetic Foot | 1 | 2011 | 352 | 0.290 |
Why?
|
Interview, Psychological | 1 | 2010 | 812 | 0.290 |
Why?
|
Software | 3 | 2019 | 4423 | 0.280 |
Why?
|
Length of Stay | 4 | 2016 | 6295 | 0.280 |
Why?
|
Ophthalmology | 2 | 2010 | 504 | 0.280 |
Why?
|
Medical Informatics | 1 | 2013 | 740 | 0.280 |
Why?
|
United States Agency for Healthcare Research and Quality | 2 | 2016 | 92 | 0.270 |
Why?
|
Research Design | 2 | 2019 | 5959 | 0.260 |
Why?
|
Monitoring, Intraoperative | 1 | 2012 | 954 | 0.260 |
Why?
|
Inpatients | 3 | 2012 | 2478 | 0.260 |
Why?
|
Medicine | 1 | 2013 | 930 | 0.250 |
Why?
|
Quality Indicators, Health Care | 2 | 2017 | 1828 | 0.250 |
Why?
|
Internship and Residency | 2 | 2016 | 5761 | 0.250 |
Why?
|
Patient Satisfaction | 3 | 2013 | 3382 | 0.250 |
Why?
|
Cardiovascular Diseases | 3 | 2023 | 15070 | 0.250 |
Why?
|
Mass Screening | 2 | 2009 | 5265 | 0.230 |
Why?
|
Medication Adherence | 2 | 2014 | 2047 | 0.220 |
Why?
|
Child Care | 1 | 2023 | 119 | 0.220 |
Why?
|
Blood Pressure | 9 | 2015 | 8554 | 0.220 |
Why?
|
Administrative Personnel | 2 | 2014 | 186 | 0.210 |
Why?
|
Patient Readmission | 1 | 2016 | 3106 | 0.210 |
Why?
|
Referral and Consultation | 4 | 2021 | 3514 | 0.210 |
Why?
|
Health Promotion | 1 | 2014 | 2187 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3143 | 0.210 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3248 | 0.210 |
Why?
|
Hyperoxia | 2 | 2015 | 264 | 0.200 |
Why?
|
Female | 40 | 2023 | 378853 | 0.200 |
Why?
|
Focus Groups | 4 | 2014 | 1308 | 0.190 |
Why?
|
Cost-Benefit Analysis | 5 | 2019 | 5462 | 0.190 |
Why?
|
Comorbidity | 6 | 2023 | 10362 | 0.190 |
Why?
|
Prediabetic State | 2 | 2018 | 484 | 0.190 |
Why?
|
Pandemics | 1 | 2020 | 8274 | 0.180 |
Why?
|
Male | 38 | 2021 | 349022 | 0.180 |
Why?
|
Adult | 34 | 2022 | 213394 | 0.170 |
Why?
|
Retinal Vessels | 3 | 2015 | 774 | 0.170 |
Why?
|
Delivery of Health Care | 5 | 2021 | 5272 | 0.170 |
Why?
|
Health Personnel | 3 | 2023 | 3203 | 0.160 |
Why?
|
Cyclic AMP | 4 | 1987 | 1470 | 0.160 |
Why?
|
San Francisco | 1 | 2018 | 159 | 0.160 |
Why?
|
Pharmacists | 1 | 2021 | 238 | 0.160 |
Why?
|
Vasodilation | 2 | 2013 | 947 | 0.160 |
Why?
|
Diabetic Ketoacidosis | 1 | 2021 | 246 | 0.160 |
Why?
|
Eating | 1 | 2005 | 1526 | 0.160 |
Why?
|
Phosphoenolpyruvate Carboxykinase (GTP) | 2 | 1996 | 38 | 0.160 |
Why?
|
Physician-Patient Relations | 1 | 2011 | 3217 | 0.160 |
Why?
|
Middle Aged | 30 | 2020 | 212863 | 0.160 |
Why?
|
Needs Assessment | 2 | 2017 | 1145 | 0.160 |
Why?
|
Diabetic Retinopathy | 3 | 2013 | 1203 | 0.160 |
Why?
|
Continuity of Patient Care | 2 | 2016 | 1054 | 0.150 |
Why?
|
Biotechnology | 1 | 2019 | 277 | 0.150 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2023 | 703 | 0.150 |
Why?
|
Islets of Langerhans | 1 | 2023 | 1337 | 0.150 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 3233 | 0.140 |
Why?
|
Endpoint Determination | 1 | 2019 | 598 | 0.140 |
Why?
|
Vasoconstriction | 2 | 2012 | 601 | 0.140 |
Why?
|
Retinal Diseases | 1 | 2023 | 687 | 0.140 |
Why?
|
Risk Factors | 8 | 2021 | 71974 | 0.140 |
Why?
|
Privacy | 1 | 2018 | 236 | 0.140 |
Why?
|
Critical Care | 3 | 2020 | 2624 | 0.140 |
Why?
|
Computers | 1 | 2018 | 614 | 0.140 |
Why?
|
Hypertension | 1 | 2016 | 8431 | 0.130 |
Why?
|
Nurse's Role | 3 | 2013 | 209 | 0.130 |
Why?
|
Tomography, Optical Coherence | 1 | 2008 | 2623 | 0.130 |
Why?
|
Alkyl and Aryl Transferases | 1 | 1996 | 90 | 0.130 |
Why?
|
Liver Glycogen | 2 | 1986 | 34 | 0.130 |
Why?
|
Health Services Accessibility | 4 | 2019 | 5128 | 0.130 |
Why?
|
Wounds and Injuries | 2 | 2007 | 2394 | 0.130 |
Why?
|
Health Knowledge, Attitudes, Practice | 4 | 2017 | 3908 | 0.130 |
Why?
|
Aged | 21 | 2024 | 162698 | 0.130 |
Why?
|
Treatment Outcome | 11 | 2019 | 62693 | 0.130 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2018 | 395 | 0.130 |
Why?
|
Coronary Artery Bypass | 1 | 2004 | 2272 | 0.120 |
Why?
|
Confidentiality | 1 | 2018 | 610 | 0.120 |
Why?
|
Nutrition Policy | 1 | 2018 | 486 | 0.120 |
Why?
|
Congresses as Topic | 1 | 2018 | 760 | 0.120 |
Why?
|
Obesity | 3 | 2023 | 12643 | 0.120 |
Why?
|
Telecommunications | 1 | 2014 | 80 | 0.120 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 1 | 1996 | 433 | 0.110 |
Why?
|
Ambulatory Care Facilities | 1 | 2019 | 928 | 0.110 |
Why?
|
Health Behavior | 3 | 2023 | 2624 | 0.110 |
Why?
|
Nurse-Patient Relations | 1 | 2013 | 101 | 0.110 |
Why?
|
Risk Reduction Behavior | 1 | 2019 | 1123 | 0.110 |
Why?
|
Practice Management | 1 | 2013 | 37 | 0.110 |
Why?
|
History, 21st Century | 1 | 2018 | 1534 | 0.110 |
Why?
|
Diabetic Angiopathies | 3 | 2015 | 821 | 0.110 |
Why?
|
Curriculum | 2 | 2016 | 3575 | 0.100 |
Why?
|
Medicare | 2 | 2024 | 6497 | 0.100 |
Why?
|
Adaptation, Psychological | 2 | 2013 | 2564 | 0.100 |
Why?
|
Lipoproteins, LDL | 2 | 2013 | 626 | 0.100 |
Why?
|
Calcium | 4 | 2006 | 5742 | 0.100 |
Why?
|
Guidelines as Topic | 1 | 2018 | 1407 | 0.100 |
Why?
|
Diagnostic Self Evaluation | 1 | 2013 | 232 | 0.100 |
Why?
|
United States Food and Drug Administration | 1 | 2018 | 1584 | 0.090 |
Why?
|
Risk Assessment | 3 | 2019 | 23294 | 0.090 |
Why?
|
Nurse Practitioners | 1 | 2014 | 270 | 0.090 |
Why?
|
Qualitative Research | 3 | 2014 | 2656 | 0.090 |
Why?
|
Perioperative Period | 1 | 2012 | 255 | 0.090 |
Why?
|
Withholding Treatment | 1 | 2014 | 596 | 0.090 |
Why?
|
Young Adult | 7 | 2021 | 56255 | 0.090 |
Why?
|
Nursing Homes | 1 | 2017 | 1029 | 0.090 |
Why?
|
Coronary Disease | 3 | 2015 | 6068 | 0.090 |
Why?
|
Injections, Subcutaneous | 1 | 2011 | 664 | 0.090 |
Why?
|
1-Methyl-3-isobutylxanthine | 2 | 1986 | 102 | 0.090 |
Why?
|
Infusions, Intravenous | 2 | 2012 | 2270 | 0.090 |
Why?
|
Education, Nursing, Continuing | 1 | 2009 | 75 | 0.090 |
Why?
|
Electrical Equipment and Supplies | 1 | 2009 | 27 | 0.080 |
Why?
|
Photic Stimulation | 2 | 2013 | 2032 | 0.080 |
Why?
|
Adolescent | 8 | 2023 | 85405 | 0.080 |
Why?
|
Cost of Illness | 2 | 2024 | 1849 | 0.080 |
Why?
|
Mentors | 1 | 2014 | 632 | 0.080 |
Why?
|
Medicaid | 2 | 2014 | 2711 | 0.080 |
Why?
|
Kidney Transplantation | 1 | 2003 | 4220 | 0.080 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2023 | 2216 | 0.080 |
Why?
|
Diabetes, Gestational | 1 | 2018 | 1174 | 0.080 |
Why?
|
Glasgow Coma Scale | 2 | 2007 | 568 | 0.080 |
Why?
|
Health Maintenance Organizations | 2 | 2002 | 644 | 0.080 |
Why?
|
Self Efficacy | 2 | 2009 | 607 | 0.080 |
Why?
|
Physicians, Primary Care | 1 | 2014 | 577 | 0.080 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2016 | 941 | 0.080 |
Why?
|
Postoperative Complications | 2 | 2016 | 15194 | 0.080 |
Why?
|
Lactates | 2 | 1986 | 434 | 0.080 |
Why?
|
Preoperative Care | 2 | 2009 | 2238 | 0.080 |
Why?
|
Quality of Life | 4 | 2019 | 12640 | 0.080 |
Why?
|
Injury Severity Score | 2 | 2007 | 1011 | 0.070 |
Why?
|
Sciatic Nerve | 1 | 1990 | 611 | 0.070 |
Why?
|
Postprandial Period | 2 | 2006 | 293 | 0.070 |
Why?
|
Overweight | 1 | 2018 | 2355 | 0.070 |
Why?
|
New York City | 1 | 2009 | 704 | 0.070 |
Why?
|
Urban Population | 1 | 2015 | 2014 | 0.070 |
Why?
|
Sebum | 1 | 2006 | 16 | 0.070 |
Why?
|
Inservice Training | 1 | 2009 | 391 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2011 | 10945 | 0.070 |
Why?
|
Sebaceous Glands | 1 | 2006 | 41 | 0.070 |
Why?
|
Oxaloacetates | 1 | 1985 | 6 | 0.070 |
Why?
|
Quinolinic Acids | 1 | 1985 | 16 | 0.070 |
Why?
|
Theophylline | 1 | 1986 | 132 | 0.070 |
Why?
|
Pressure Ulcer | 1 | 2007 | 154 | 0.070 |
Why?
|
Nursing Staff, Hospital | 1 | 2009 | 346 | 0.070 |
Why?
|
Fenofibrate | 1 | 2006 | 89 | 0.070 |
Why?
|
Pyruvates | 1 | 1985 | 86 | 0.070 |
Why?
|
Decision Making | 2 | 2018 | 3854 | 0.070 |
Why?
|
Protein Kinase C | 1 | 1990 | 1223 | 0.070 |
Why?
|
Drug Utilization | 1 | 2012 | 1181 | 0.070 |
Why?
|
Faculty, Medical | 1 | 2014 | 1179 | 0.060 |
Why?
|
3',5'-Cyclic-AMP Phosphodiesterases | 1 | 1985 | 50 | 0.060 |
Why?
|
Health Services Research | 1 | 2013 | 1832 | 0.060 |
Why?
|
Enteral Nutrition | 1 | 2011 | 758 | 0.060 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 1986 | 215 | 0.060 |
Why?
|
Hyperlipidemias | 2 | 2007 | 785 | 0.060 |
Why?
|
Retrospective Studies | 7 | 2021 | 76631 | 0.060 |
Why?
|
Brachial Artery | 1 | 2006 | 370 | 0.060 |
Why?
|
Liver | 5 | 2023 | 7449 | 0.060 |
Why?
|
PPAR alpha | 1 | 2006 | 196 | 0.060 |
Why?
|
Survival Analysis | 1 | 2017 | 10247 | 0.060 |
Why?
|
Gluconeogenesis | 1 | 1985 | 183 | 0.060 |
Why?
|
United States Department of Veterans Affairs | 1 | 2009 | 873 | 0.060 |
Why?
|
Gas Chromatography-Mass Spectrometry | 1 | 2005 | 361 | 0.060 |
Why?
|
Education, Medical, Continuing | 1 | 2010 | 840 | 0.060 |
Why?
|
Education, Medical, Graduate | 1 | 2016 | 2275 | 0.060 |
Why?
|
Database Management Systems | 1 | 2005 | 272 | 0.060 |
Why?
|
Diabetes Mellitus, Experimental | 1 | 1990 | 1125 | 0.060 |
Why?
|
Lipolysis | 1 | 1985 | 211 | 0.060 |
Why?
|
Information Dissemination | 1 | 2012 | 1106 | 0.060 |
Why?
|
Reference Values | 2 | 2008 | 4983 | 0.060 |
Why?
|
Hemostasis | 1 | 2006 | 459 | 0.060 |
Why?
|
Glycemic Index | 1 | 2006 | 395 | 0.060 |
Why?
|
Counseling | 1 | 2011 | 1526 | 0.060 |
Why?
|
Medical Records | 1 | 2009 | 1413 | 0.060 |
Why?
|
Consensus | 2 | 2022 | 2913 | 0.060 |
Why?
|
Glucose | 3 | 2006 | 4377 | 0.060 |
Why?
|
Glucose Tolerance Test | 1 | 2006 | 1149 | 0.060 |
Why?
|
Administration, Oral | 2 | 2008 | 3909 | 0.060 |
Why?
|
Morbidity | 1 | 2009 | 1763 | 0.060 |
Why?
|
PPAR gamma | 1 | 2006 | 494 | 0.060 |
Why?
|
Cataract | 1 | 2009 | 825 | 0.050 |
Why?
|
Documentation | 1 | 2009 | 861 | 0.050 |
Why?
|
Clinical Competence | 2 | 2016 | 4671 | 0.050 |
Why?
|
Child Day Care Centers | 1 | 2023 | 124 | 0.050 |
Why?
|
Pilot Projects | 3 | 2015 | 8275 | 0.050 |
Why?
|
Glutamate Decarboxylase | 1 | 2023 | 246 | 0.050 |
Why?
|
International Cooperation | 1 | 2009 | 1420 | 0.050 |
Why?
|
Social Support | 1 | 2012 | 2112 | 0.050 |
Why?
|
Rats, Inbred Strains | 3 | 1990 | 2198 | 0.050 |
Why?
|
4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone | 3 | 1986 | 7 | 0.050 |
Why?
|
Aging | 1 | 2020 | 8613 | 0.050 |
Why?
|
Hypolipidemic Agents | 1 | 2006 | 606 | 0.050 |
Why?
|
Urinary Tract Infections | 1 | 2007 | 766 | 0.050 |
Why?
|
Epinephrine | 1 | 1985 | 795 | 0.050 |
Why?
|
Predictive Value of Tests | 3 | 2019 | 15036 | 0.050 |
Why?
|
Dietary Carbohydrates | 1 | 2006 | 904 | 0.050 |
Why?
|
Rats | 8 | 2000 | 24270 | 0.050 |
Why?
|
Ultrasonography, Doppler, Pulsed | 1 | 2000 | 19 | 0.050 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2006 | 1504 | 0.040 |
Why?
|
Cross-Over Studies | 1 | 2005 | 2030 | 0.040 |
Why?
|
Aged, 80 and over | 6 | 2020 | 57650 | 0.040 |
Why?
|
Glaucoma | 1 | 2009 | 1140 | 0.040 |
Why?
|
Drug Therapy, Combination | 2 | 2007 | 6478 | 0.040 |
Why?
|
Regional Blood Flow | 2 | 2013 | 1528 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2021 | 9812 | 0.040 |
Why?
|
Drug Administration Schedule | 1 | 2007 | 4935 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2008 | 5058 | 0.040 |
Why?
|
Incidence | 1 | 2016 | 20913 | 0.040 |
Why?
|
Evidence-Based Medicine | 1 | 2010 | 3606 | 0.040 |
Why?
|
Surgical Procedures, Operative | 1 | 2009 | 1867 | 0.040 |
Why?
|
Health Status | 2 | 2009 | 4013 | 0.040 |
Why?
|
Treatment Failure | 1 | 2003 | 2614 | 0.040 |
Why?
|
Diabetic Nephropathies | 1 | 2004 | 981 | 0.040 |
Why?
|
Mid-Atlantic Region | 1 | 2016 | 23 | 0.040 |
Why?
|
Postoperative Care | 1 | 2004 | 1477 | 0.040 |
Why?
|
Culture Media | 1 | 2019 | 902 | 0.040 |
Why?
|
Arrhythmias, Cardiac | 1 | 2007 | 2265 | 0.040 |
Why?
|
Enzyme Activation | 2 | 1996 | 3701 | 0.040 |
Why?
|
Preconception Care | 1 | 2018 | 135 | 0.040 |
Why?
|
Angioplasty, Balloon, Coronary | 1 | 2004 | 1874 | 0.040 |
Why?
|
Transferases | 1 | 1996 | 76 | 0.030 |
Why?
|
Respiration, Artificial | 1 | 2007 | 2560 | 0.030 |
Why?
|
Farnesyltranstransferase | 1 | 1996 | 76 | 0.030 |
Why?
|
Chromones | 1 | 1996 | 155 | 0.030 |
Why?
|
Europe | 1 | 2022 | 3331 | 0.030 |
Why?
|
Arteriosclerosis | 1 | 2000 | 1092 | 0.030 |
Why?
|
8-Bromo Cyclic Adenosine Monophosphate | 2 | 1986 | 76 | 0.030 |
Why?
|
Body Mass Index | 3 | 2009 | 12655 | 0.030 |
Why?
|
Pneumonia | 1 | 2007 | 2102 | 0.030 |
Why?
|
Autoantibodies | 1 | 2023 | 2020 | 0.030 |
Why?
|
Acute Kidney Injury | 1 | 2007 | 1941 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2015 | 21694 | 0.030 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1996 | 494 | 0.030 |
Why?
|
Arterioles | 1 | 2015 | 253 | 0.030 |
Why?
|
Child | 5 | 2023 | 77033 | 0.030 |
Why?
|
Pyridines | 1 | 1985 | 2810 | 0.030 |
Why?
|
Kinetics | 3 | 1987 | 6475 | 0.030 |
Why?
|
Liver Cirrhosis | 1 | 2023 | 1838 | 0.030 |
Why?
|
Sepsis | 1 | 2007 | 2571 | 0.030 |
Why?
|
Survival Rate | 1 | 2007 | 12761 | 0.030 |
Why?
|
Morpholines | 1 | 1996 | 562 | 0.030 |
Why?
|
Adipose Tissue | 1 | 1985 | 3280 | 0.030 |
Why?
|
Patient Care Planning | 1 | 2018 | 918 | 0.030 |
Why?
|
Cardiomyopathies | 1 | 2004 | 1911 | 0.030 |
Why?
|
Health Services Needs and Demand | 2 | 2012 | 1409 | 0.030 |
Why?
|
Pluripotent Stem Cells | 1 | 2019 | 791 | 0.030 |
Why?
|
Monitoring, Physiologic | 1 | 2000 | 1735 | 0.030 |
Why?
|
Goals | 1 | 2017 | 702 | 0.030 |
Why?
|
Mitral Valve | 1 | 2000 | 1483 | 0.030 |
Why?
|
Time Factors | 3 | 2019 | 40050 | 0.030 |
Why?
|
Follow-Up Studies | 1 | 2013 | 38942 | 0.030 |
Why?
|
Calcinosis | 1 | 2000 | 1493 | 0.020 |
Why?
|
Heart Rate | 2 | 2013 | 4095 | 0.020 |
Why?
|
Trifluoperazine | 1 | 1990 | 40 | 0.020 |
Why?
|
Asthma | 1 | 2010 | 5950 | 0.020 |
Why?
|
Polymyxin B | 1 | 1990 | 46 | 0.020 |
Why?
|
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 1990 | 57 | 0.020 |
Why?
|
Health Expenditures | 1 | 2024 | 2348 | 0.020 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 1996 | 1213 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 1987 | 5502 | 0.020 |
Why?
|
Geriatric Assessment | 1 | 2018 | 1366 | 0.020 |
Why?
|
Graft Rejection | 1 | 2003 | 4379 | 0.020 |
Why?
|
Lactic Acid | 2 | 1986 | 1132 | 0.020 |
Why?
|
Stem Cell Transplantation | 1 | 2019 | 1628 | 0.020 |
Why?
|
Diglycerides | 1 | 1990 | 176 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 2017 | 1778 | 0.020 |
Why?
|
Nursing Education Research | 1 | 2009 | 12 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2008 | 19811 | 0.020 |
Why?
|
Chromatography, Gel | 1 | 1990 | 672 | 0.020 |
Why?
|
Blood Flow Velocity | 2 | 2006 | 1437 | 0.020 |
Why?
|
Nursing Methodology Research | 1 | 2009 | 67 | 0.020 |
Why?
|
Models, Nursing | 1 | 2009 | 44 | 0.020 |
Why?
|
Depression | 1 | 2009 | 7689 | 0.020 |
Why?
|
Phosphatidylserines | 1 | 1990 | 192 | 0.020 |
Why?
|
Coronary Circulation | 1 | 2015 | 1578 | 0.020 |
Why?
|
Hospitals | 1 | 2023 | 3916 | 0.020 |
Why?
|
Pregnancy | 2 | 2023 | 29002 | 0.020 |
Why?
|
Isoquinolines | 1 | 1990 | 371 | 0.020 |
Why?
|
Oxygen Consumption | 1 | 2015 | 1871 | 0.020 |
Why?
|
Program Evaluation | 1 | 2017 | 2484 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 1996 | 1674 | 0.020 |
Why?
|
Societies | 1 | 2008 | 105 | 0.020 |
Why?
|
Transfection | 1 | 1996 | 5884 | 0.020 |
Why?
|
Prospective Studies | 2 | 2022 | 53037 | 0.020 |
Why?
|
Hospitalization | 1 | 2007 | 10208 | 0.020 |
Why?
|
Writing | 1 | 2009 | 205 | 0.020 |
Why?
|
Total Quality Management | 1 | 2008 | 274 | 0.020 |
Why?
|
Phospholipids | 1 | 1990 | 783 | 0.020 |
Why?
|
Phenylisopropyladenosine | 1 | 1986 | 14 | 0.020 |
Why?
|
Gemfibrozil | 1 | 2006 | 30 | 0.020 |
Why?
|
Health Surveys | 2 | 2010 | 4022 | 0.020 |
Why?
|
Models, Educational | 1 | 2009 | 377 | 0.020 |
Why?
|
Skin | 1 | 2000 | 4324 | 0.020 |
Why?
|
Concanavalin A | 1 | 1986 | 192 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 1996 | 2933 | 0.020 |
Why?
|
Aminoquinolines | 1 | 1986 | 108 | 0.020 |
Why?
|
Quinolinic Acid | 1 | 1985 | 68 | 0.020 |
Why?
|
Asparagine | 1 | 1985 | 123 | 0.020 |
Why?
|
Oleic Acid | 1 | 1985 | 85 | 0.020 |
Why?
|
Oleic Acids | 1 | 1985 | 70 | 0.020 |
Why?
|
Isotretinoin | 1 | 2006 | 111 | 0.020 |
Why?
|
Phenylephrine | 1 | 1986 | 302 | 0.020 |
Why?
|
Animals | 8 | 2000 | 168368 | 0.020 |
Why?
|
Insulin, Long-Acting | 1 | 2005 | 57 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 1996 | 3802 | 0.020 |
Why?
|
Hemodynamics | 1 | 2015 | 4197 | 0.020 |
Why?
|
Risk | 1 | 2017 | 9684 | 0.020 |
Why?
|
Cell Line, Transformed | 1 | 2006 | 897 | 0.020 |
Why?
|
Pyruvic Acid | 1 | 1985 | 197 | 0.020 |
Why?
|
Lipogenesis | 1 | 2006 | 210 | 0.020 |
Why?
|
Vasopressins | 1 | 1986 | 370 | 0.020 |
Why?
|
Macromolecular Substances | 1 | 1987 | 1457 | 0.020 |
Why?
|
Insurance Claim Review | 1 | 2008 | 720 | 0.010 |
Why?
|
Community Health Services | 1 | 2008 | 652 | 0.010 |
Why?
|
Thiazolidinediones | 1 | 2006 | 474 | 0.010 |
Why?
|
Cytosol | 1 | 1985 | 902 | 0.010 |
Why?
|
Area Under Curve | 1 | 2006 | 1655 | 0.010 |
Why?
|
Clinical Protocols | 1 | 2008 | 1453 | 0.010 |
Why?
|
Drug Monitoring | 1 | 2008 | 961 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2013 | 3752 | 0.010 |
Why?
|
Trauma Centers | 1 | 2006 | 888 | 0.010 |
Why?
|
Structure-Activity Relationship | 1 | 1987 | 3146 | 0.010 |
Why?
|
Benchmarking | 1 | 2008 | 1034 | 0.010 |
Why?
|
Child, Preschool | 1 | 2023 | 40802 | 0.010 |
Why?
|
Lipids | 1 | 2012 | 3307 | 0.010 |
Why?
|
Sulfonamides | 1 | 1990 | 1934 | 0.010 |
Why?
|
RNA, Messenger | 1 | 1996 | 13002 | 0.010 |
Why?
|
Piperazines | 1 | 1990 | 2480 | 0.010 |
Why?
|
Cells, Cultured | 1 | 1996 | 19220 | 0.010 |
Why?
|
Point-of-Care Systems | 1 | 2008 | 1175 | 0.010 |
Why?
|
Echocardiography, Doppler, Color | 1 | 2000 | 364 | 0.010 |
Why?
|
Diet | 1 | 2017 | 7876 | 0.010 |
Why?
|
Ligands | 1 | 2006 | 3311 | 0.010 |
Why?
|
Metformin | 1 | 2005 | 827 | 0.010 |
Why?
|
Lipoproteins, HDL | 1 | 2002 | 643 | 0.010 |
Why?
|
Critical Illness | 1 | 2008 | 2656 | 0.010 |
Why?
|
Myocardial Contraction | 1 | 2000 | 1585 | 0.010 |
Why?
|
Anxiety | 1 | 2009 | 4253 | 0.010 |
Why?
|
Protein Binding | 1 | 1987 | 9375 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2015 | 24714 | 0.010 |
Why?
|
Body Weight | 1 | 2005 | 4660 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2009 | 13880 | 0.010 |
Why?
|
Prognosis | 2 | 2006 | 28901 | 0.010 |
Why?
|
Cholesterol | 1 | 2002 | 2900 | 0.010 |
Why?
|
Signal Transduction | 1 | 1996 | 23355 | 0.010 |
Why?
|
Heart Valve Diseases | 1 | 2000 | 1058 | 0.010 |
Why?
|
Logistic Models | 1 | 2006 | 13402 | 0.010 |
Why?
|
Models, Biological | 1 | 2008 | 9609 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 2000 | 8299 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2002 | 7726 | 0.000 |
Why?
|
Algorithms | 1 | 2008 | 13872 | 0.000 |
Why?
|
Severity of Illness Index | 1 | 2000 | 15511 | 0.000 |
Why?
|